Screening of the Filamin C Gene in a Large Cohort of Hypertrophic Cardiomyopathy Patients

Background— Recent exome sequencing studies identified filamin C (FLNC) as a candidate gene for hypertrophic cardiomyopathy (HCM). Our aim was to determine the rate of FLNC candidate variants in a large cohort of HCM patients who were also sequenced for the main sarcomere genes. Methods and Results— A total of 448 HCM patients were next generation–sequenced (semiconductor chip technology) for the MYH7, MYBPC3, TNNT2, TNNI3, ACTC1, TNNC1, MYL2, MYL3, TPM1, and FLNC genes. We also sequenced 450 healthy controls from the same population. Based on the reported population frequencies, bioinformatic criteria, and familial segregation, we identified 20 FLNC candidate variants (13 new; 1 nonsense; and 19 missense) in 22 patients. Compared with the patients, only 1 of the control’s missense variants was nonreported (P=0.007; Fisher exact probability test). Based on the familial segregation and the reported functional studies, 6 of the candidate variants (in 7 patients) were finally classified as likely pathogenic, 10 as variants of uncertain significance, and 4 as likely benign. Conclusions— We provide a compelling evidence of the involvement of FLNC in the development of HCM. Most of the FLNC variants were associated with mild forms of HCM and a reduced penetrance, with few affected in the families to confirm the segregation. Our work, together with others who found FLNC variants among patients with dilated and restrictive cardiomyopathies, pointed to this gene as an important cause of structural cardiomyopathies.

[1]  X. Puente,et al.  Congenital dilated cardiomyopathy caused by biallelic mutations in Filamin C , 2016, European Journal of Human Genetics.

[2]  V. Álvarez,et al.  KCNQ1 gene variants in the risk for type 2 diabetes and impaired renal function in the Spanish Renastur cohort , 2016, Molecular and Cellular Endocrinology.

[3]  L. Monserrat,et al.  Genetic basis of familial dilated cardiomyopathy patients undergoing heart transplantation. , 2016, The Journal of Heart and Lung Transplantation.

[4]  J. Schwartzentruber,et al.  Mutations in FLNC are Associated with Familial Restrictive Cardiomyopathy , 2016, Human mutation.

[5]  M. Ackerman,et al.  Genetic purgatory and the cardiac channelopathies: Exposing the variants of uncertain/unknown significance issue. , 2015, Heart rhythm.

[6]  J. Southern,et al.  BAG3 myofibrillar myopathy presenting with cardiomyopathy , 2015, Neuromuscular Disorders.

[7]  H. Rehm,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[8]  Y. Pinto,et al.  Genetic advances in sarcomeric cardiomyopathies: state of the art , 2015, Cardiovascular research.

[9]  Lorenzo L. Pesce,et al.  Targeted Analysis of Whole Genome Sequence Data to Diagnose Genetic Cardiomyopathy , 2014, Circulation. Cardiovascular genetics.

[10]  V. Álvarez,et al.  Mutation analysis of the main hypertrophic cardiomyopathy genes using multiplex amplification and semiconductor next-generation sequencing. , 2014, Circulation journal : official journal of the Japanese Circulation Society.

[11]  X. Puente,et al.  Mutations in filamin C cause a new form of familial hypertrophic cardiomyopathy , 2014, Nature Communications.

[12]  Giuseppe Limongelli,et al.  A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). , 2014, European heart journal.

[13]  E. Coto,et al.  Effect of the FTO rs9930506 Polymorphism on the Main Comorbidities of the Cardiorenal Metabolic Syndrome in an Elderly Spanish Cohort , 2014, Cardiorenal Medicine.

[14]  J. Shendure,et al.  A general framework for estimating the relative pathogenicity of human genetic variants , 2014, Nature Genetics.

[15]  V. Álvarez,et al.  Non Optical Semi-Conductor Next Generation Sequencing of the Main Cardiac QT-Interval Duration Genes in Pooled DNA Samples , 2014, Journal of Cardiovascular Translational Research.

[16]  J. Kautzner,et al.  Isolated X-Linked Hypertrophic Cardiomyopathy Caused by a Novel Mutation of the Four-and-a-Half LIM Domain 1 Gene , 2013, Circulation. Cardiovascular genetics.

[17]  V. Álvarez,et al.  The G263X MYBPC3 mutation is a common and low-penetrant mutation for hypertrophic cardiomyopathy in the region of Asturias (Northern Spain). , 2013, International journal of cardiology.

[18]  G. Bonne,et al.  ‘State-of-the-heart’ of cardiac laminopathies , 2013, Current opinion in cardiology.

[19]  Katherine H. Schreiber,et al.  When Lamins Go Bad: Nuclear Structure and Disease , 2013, Cell.

[20]  Claudia Giambartolomei,et al.  Genetic complexity in hypertrophic cardiomyopathy revealed by high-throughput sequencing , 2013, Journal of Medical Genetics.

[21]  J. Svendsen,et al.  New population-based exome data are questioning the pathogenicity of previously cardiomyopathy-associated genetic variants , 2013, European Journal of Human Genetics.

[22]  S. Gabriel,et al.  Burden of rare sarcomere gene variants in the Framingham and Jackson Heart Study cohorts. , 2012, American journal of human genetics.

[23]  Donald Wolfgeher,et al.  Population-Based Variation in Cardiomyopathy Genes , 2012, Circulation. Cardiovascular genetics.

[24]  Eloisa Arbustini,et al.  Evidence for FHL1 as a novel disease gene for isolated hypertrophic cardiomyopathy. , 2012, Human molecular genetics.

[25]  Robert H. Brown,et al.  Mutations in the N-terminal actin-binding domain of filamin C cause a distal myopathy. , 2011, American journal of human genetics.

[26]  A. Gonzalez-Perez,et al.  Improving the assessment of the outcome of nonsynonymous SNVs with a consensus deleteriousness score, Condel. , 2011, American journal of human genetics.

[27]  P. Bork,et al.  A method and server for predicting damaging missense mutations , 2010, Nature Methods.

[28]  I. Ferrer,et al.  In-frame deletion in the seventh immunoglobulin-like repeat of filamin C in a family with myofibrillar myopathy , 2009, European Journal of Human Genetics.

[29]  C. Heyer,et al.  Clinical and morphological phenotype of the filamin myopathy: a study of 31 German patients. , 2007, Brain : a journal of neurology.

[30]  T. Holak,et al.  Filamins: promiscuous organizers of the cytoskeleton. , 2006, Trends in biochemical sciences.

[31]  H. Wajcman,et al.  In silico prediction of the deleterious effect of a mutation: proceed with caution in clinical genetics. , 2004, Clinical chemistry.

[32]  C. Walsh,et al.  The many faces of filamin: A versatile molecular scaffold for cell motility and signalling , 2004, Nature Cell Biology.

[33]  F. Mastaglia,et al.  Mutations in the slow skeletal muscle fiber myosin heavy chain gene (MYH7) cause laing early-onset distal myopathy (MPD1). , 2004, American journal of human genetics.

[34]  E. Coto,et al.  The Ups and Downs of Genetic Diagnosis of Hypertrophic Cardiomyopathy. , 2016, Revista espanola de cardiologia.

[35]  M. Vorgerd,et al.  Filamin C-related myopathies: pathology and mechanisms , 2012, Acta Neuropathologica.

[36]  S. Henikoff,et al.  Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm , 2009, Nature Protocols.